For fiscal year 2023, Dr\u00e4gerwerk AG & Co. KGaA (Dr\u00e4ger), based in L\u00fcbeck, recently reported a positive development.<\/p>\n
The family-owned company, which specialises in medical and safety technology, generated sales of around 3.4 billion euros in 2023. This corresponds to an increase of 13.1 percent compared to the 2022 financial year, when net sales were around EUR 3.0 billion. Dr\u00e4ger recorded net sales growth in both its medical technology and safety technology divisions. As the company explains, both segments benefited in the 2023 financial year from an improved Delivery capability<\/strong> and a positive order trend.<\/p>\n Dr\u00e4ger reports that it has also significantly improved its profitability. Accordingly, earnings before interest and taxes (EBIT) increased to 166.4 million euros. In 2022, the company still generated a negative EBIT (-88.6 million euros). In terms of the EBIT margin, Dr\u00e4ger announced an increase of 7.8 percentage points - from -2.9 percent in 2022 to 4.9 percent in 2023.<\/p>\n \u201eIn 2023, we returned to growth and profitability as promised and even exceeded our original forecast for the year,\u201c says Stefan Dr\u00e4ger, CEO of Dr\u00e4gerwerk Verwaltungs AG. In addition to strong sales growth, the profit was also due to a successful Cost management<\/em> attributable.<\/p>\n According to Stefan Dr\u00e4ger, a significantly higher dividend for 2023 compared to the previous year will be proposed to the upcoming Annual General Meeting. The plan is to distribute a dividend of EUR 1.74 per ordinary share and EUR 1.80 per preference share. This is EUR 1.61 per share more than a year earlier. <\/p>\n According to its press release, Dr\u00e4ger anticipates currency-adjusted net sales growth of 1.0 to 5.0 percent in 2024. The L\u00fcbeck-based technology company also expects an EBIT margin of 2.5 to 5.5 percent.<\/p>\n With regard to its forecast, Dr\u00e4ger explains that there were still two effects in 2023 that had a positive impact on net sales and earnings. According to the company, growth and profitability in 2023 were supported by catch-up effects as a result of the improvement in the previously limited delivery capacity. There was also a wave of demand for ventilators in China at the beginning of 2023. According to the family-owned company, these two effects are now missing in the current financial year.<\/p>","protected":false},"excerpt":{"rendered":" Mehr Umsatz und Gewinn, h\u00f6here Dividende F\u00fcr das Gesch\u00e4ftsjahr 2023 konnte die Dr\u00e4gerwerk AG & Co. KGaA (Dr\u00e4ger) mit Sitz in L\u00fcbeck k\u00fcrzlich \u00fcber eine positive Entwicklung berichten. So hat das auf Medizin- und auf Sicherheitstechnik spezialisierte Familienunternehmen 2023 einen Umsatz von rund 3,4 Millarden Euro erzielt. Das entspricht einer Steigerung um 13,1 Prozent gegen\u00fcber […]<\/p>\n","protected":false},"author":1,"featured_media":11272,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88],"tags":[],"referenzkategorie":[],"class_list":["post-11271","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-supply-chain-news"],"acf":[],"yoast_head":"\nHigher profitability<\/h3>\n
Forecast for 2024<\/h3>\n